Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Xavier M, Teitsma"'
Autor:
Xavier M Teitsma, Jenny Devenport, Johannes W G Jacobs, Attila Pethö-Schramm, Michelle E A Borm, Petra Budde, Johannes W J Bijlsma, Floris P J G Lafeber
Publikováno v:
PLoS ONE, Vol 15, Iss 12, p e0241189 (2020)
BackgroundWe sought to identify immunoglobin G autoantibodies predictive of early treatment response to methotrexate, the recommended first-line therapy for patients with newly diagnosed rheumatoid arthritis, and to the interleukin-6 receptor inhibit
Externí odkaz:
https://doaj.org/article/557adbab940945f3954d2ed95caccb31
Autor:
Xavier M Teitsma, Wei Yang, Johannes W G Jacobs, Attila Pethö-Schramm, Michelle E A Borm, Amy C Harms, Thomas Hankemeier, Jacob M van Laar, Johannes W J Bijlsma, Floris P J G Lafeber
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-11 (2018)
Abstract Background We previously identified, in newly diagnosed rheumatoid arthritis (RA) patients, networks of co-expressed genes and proteomic biomarkers associated with achieving sustained drug-free remission (sDFR) after treatment with tocilizum
Externí odkaz:
https://doaj.org/article/923d9bb128b44553be1161301bed5ce1
Autor:
Xavier M. Teitsma, Johannes W. G. Jacobs, Michal Mokry, Michelle E. A. Borm, Attila Pethö-Schramm, Jacob M. van Laar, Johannes W. J. Bijlsma, Floris P. J. Lafeber
Publikováno v:
Arthritis Research & Therapy, Vol 19, Iss 1, Pp 1-10 (2017)
Abstract Background Methotrexate is endorsed to be used as first-line treatment in rheumatoid arthritis (RA). However, a large proportion of patients need additional treatment with a biological disease-modifying anti-rheumatic drug (DMARD) to adequat
Externí odkaz:
https://doaj.org/article/38624401be314537abe805db9fd77dfc
Autor:
Samantha C. Burnham, Valory N. Pavlik, Rachelle Doody, Catherine Helmer, Ronald C. Petersen, Karine Pérès, Preciosa M. Coloma, Oskar Hansson, Sebastian Palmqvist, Lesley M. Butler, Joseph S. Kass, Maria Vassilaki, Mary Sano, Erik Stomrud, Colin L. Masters, Xavier M Teitsma, Jean-François Dartigues, Concord-Ad investigators
Publikováno v:
Journal of Alzheimer's Disease
Journal of Alzheimer's Disease, 2021, 85 (1), pp.31-45. ⟨10.3233/jad-210525⟩
Journal of Alzheimer's Disease, 2021, 85 (1), pp.31-45. ⟨10.3233/jad-210525⟩
International audience; Longitudinal observational cohort studies are being conducted worldwide to understand cognition, biomarkers, and the health of the aging population better. Cross-cohort comparisons and networks of registries in Alzheimer's dis
Autor:
Mihaela V. Georgieva, Neema Lema, Lesley M. Butler, Raluca Ionescu-Ittu, Urvi Desai, JingJing Zhu, Thomas Kulalert, Keith A. Betts, Xavier M Teitsma, Paul Delmar, Julie Mouchet
Publikováno v:
Journal of Alzheimer's Disease
Background: Progression trajectories of patients with mild cognitive impairment (MCI) are currently not well understood. Objective: To classify patients with incident MCI into different latent classes of progression and identify predictors of progres
Autor:
Yves Luder, Mary Safy-Khan, Xavier M Teitsma, Johannes W. J. Bijlsma, Maria J.H. de Hair, Attila Pethoe-Schramm, Johannes W G Jacobs, Paco M J Welsing, Michael D Edwardes, Jacob M van Laar, Jenny Devenport
Publikováno v:
Annals of the Rheumatic Diseases. 79:460-463
BackgroundIn rheumatoid arthritis (RA) trials, inclusion of patients on background treatment with glucocorticoids (GCs) might impact efficacy and safety outcomes.ObjectivesTo determine if inclusion of patients on background GC use influenced efficacy
Autor:
Michelle E A Borm, Suzanne P. Linn-Rasker, Marjolein J.H. de Hair, Johannes W G Jacobs, Floris P J G Lafeber, Attila Pethoe-Schramm, Jacob M van Laar, Xavier M Teitsma, Paco M J Welsing, Janneke Tekstra, Johannes W. J. Bijlsma, Maxime Verhoeven, Evert Jan ter Borg
Publikováno v:
Annals of the Rheumatic Diseases. 78:1333-1338
Objectives Methotrexate (MTX), often combined with low moderately dosed prednisone, is still the cornerstone of initial treatment for early rheumatoid arthritis (RA). It is not known how this strategy compares with initial treatment with a biological
Autor:
Floris P J G Lafeber, Petra Budde, Johannes W. J. Bijlsma, Xavier M Teitsma, Johannes W G Jacobs, Attila Pethö-Schramm, Jenny Devenport, Michelle E A Borm
Publikováno v:
PLoS ONE, Vol 15, Iss 12, p e0241189 (2020)
PLoS ONE
PLoS ONE
Background We sought to identify immunoglobin G autoantibodies predictive of early treatment response to methotrexate, the recommended first-line therapy for patients with newly diagnosed rheumatoid arthritis, and to the interleukin-6 receptor inhibi
Autor:
Maxime Ma, Verhoeven, Marjolein Jh, de Hair, Janneke, Tekstra, Johannes Wj, Bijlsma, Jacob M, van Laar, Attila, Pethoe-Schramm, Michelle Ea, Borm, Evert-Jan, Ter Borg, Suzanne P, Linn-Rasker, Xavier M, Teitsma, Floris Pjg, Lafeber, Johannes Wg, Jacobs, Paco Mj, Welsing
Publikováno v:
Annals of the rheumatic diseases. 78(10)
Methotrexate (MTX), often combined with low moderately dosed prednisone, is still the cornerstone of initial treatment for early rheumatoid arthritis (RA). It is not known how this strategy compares with initial treatment with a biological. We theref
Autor:
Johannes W. J. Bijlsma, Jacob M van Laar, Johannes W G Jacobs, Thomas Hankemeier, Floris P J G Lafeber, Xavier M Teitsma, Attila Pethö-Schramm, Amy C. Harms, Michelle E A Borm, Wei Yang
Publikováno v:
Arthritis Research & Therapy, 20, 230
Arthritis Research & Therapy
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-11 (2018)
Arthritis Research & Therapy
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-11 (2018)
Background We previously identified, in newly diagnosed rheumatoid arthritis (RA) patients, networks of co-expressed genes and proteomic biomarkers associated with achieving sustained drug-free remission (sDFR) after treatment with tocilizumab- or me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92fc2640e0b0e8029623d0caa70e3110
https://doi.org/10.1186/s13075-018-1729-2
https://doi.org/10.1186/s13075-018-1729-2